Silke van Koningsbruggen-Rietschel
Overview
Explore the profile of Silke van Koningsbruggen-Rietschel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
427
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Southern K, Castellani C, Lammertyn E, Smyth A, VanDevanter D, van Koningsbruggen-Rietschel S, et al.
J Cyst Fibros
. 2023 Mar;
22(1):17-30.
PMID: 36916675
Cystic fibrosis (CF) has entered the era of variant-specific therapy, tailored to the genetic variants in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene. CFTR modulators, the first variant-specific therapy...
12.
Habener A, Grychtol R, Gaedcke S, DeLuca D, Dittrich A, Happle C, et al.
Eur Respir J
. 2022 May;
60(5).
PMID: 35595320
Background: Comprehensive studies investigated the role of T-cells in asthma which led to personalised treatment options targeting severe eosinophilic asthma. However, little is known about the contribution of B-cells to...
13.
Maison N, Omony J, Illi S, Thiele D, Skevaki C, Dittrich A, et al.
Eur Respir J
. 2022 Feb;
60(3).
PMID: 35210326
Rationale: In adults, personalised asthma treatment targets patients with type 2 (T2)-high and eosinophilic asthma phenotypes. It is unclear whether such classification is achievable in children. Objectives: To define T2-high...
14.
Meyer M, Ruebsteck E, Eifinger F, Klein F, Oberthuer A, van Koningsbruggen-Rietschel S, et al.
J Infect Dis
. 2022 Feb;
226(12):2050-2053.
PMID: 35172330
The aim of this retrospective analysis was to provide information on how infections with respiratory syncytial virus (RSV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) differ in symptoms, clinical...
15.
van Koningsbruggen-Rietschel S, Dunlevy F, Bulteel V, Hayes K, Verbrugge A, Janssens H, et al.
Trials
. 2021 Aug;
22(1):578.
PMID: 34454570
The SARS-CoV-2 pandemic has disrupted clinical trials worldwide. The European Cystic Fibrosis Society-Clinical Trials Network (ECFS-CTN) has tracked clinical trial disruption by surveying its 58 trial sites across 17 European...
16.
Thomassen J, Trojan T, Walz M, Vohlen C, Fink G, Rietschel E, et al.
ERJ Open Res
. 2021 Jul;
7(3).
PMID: 34291109
Research Question: Pulmonary disease progression in patients with cystic fibrosis (CF) is characterised by inflammation and fibrosis and aggravated by (Pa). We investigated the impact of Pa specifically on: 1)...
17.
Naehrlich L, Orenti A, Dunlevy F, Kasmi I, Harutyunyan S, Pfleger A, et al.
J Cyst Fibros
. 2021 May;
20(4):566-577.
PMID: 34016559
Background: Viral infections can cause significant morbidity in cystic fibrosis (CF). The current Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic could therefore have a serious impact on the health...
18.
van Koningsbruggen-Rietschel S, Davies J, Pressler T, Fischer R, MacGregor G, Donaldson S, et al.
ERJ Open Res
. 2020 Oct;
6(4).
PMID: 33123558
Background: OligoG is a low molecular-weight alginate oligosaccharide that improves the viscoelastic properties of cystic fibrosis (CF) mucus and disrupts biofilms, thereby potentiating the activity of antimicrobial agents. The efficacy...
19.
van Koningsbruggen-Rietschel S
Am J Respir Crit Care Med
. 2020 Oct;
203(5):536-537.
PMID: 33113333
No abstract available.
20.
van Koningsbruggen-Rietschel S, Dunlevy F, Bulteel V, Downey D, Dupont L
Eur Respir J
. 2020 Aug;
56(3).
PMID: 32764115
No abstract available.